2 results
Approved WMOPending
The primary objective is to determine to what extent T-TEER on top of SOC reduce mortality and hospitalizations for heart failure, and improve QoL at 12 months, compared to SOC alone, in patients with severe symptomatic tricuspid valve regurgitation…
Approved WMORecruiting
Primary:• To evaluate the safety of ORGN001 (formerly ALXN1101) over the first 6 months of treatmentSecondary:• To characterize the pharmacokinetics (PK) of increasing doses of ORGN001 (formerly ALXN1101) • To evaluate the effect of ORGN001 (…